Related Experiment Videos
5-HT2 receptors, roles and regulation
1Department of Biochemical Pharmacology, Janssen Research Foundation, Beerse, Belgium.
Abstract:
Stimulation of 5-HT2 receptors in mammals by agonists causes detrimental neurological, psychological, and circulatory effects. 5-HT2 antagonists block the elicited effects, but by themselves, they do not cause any apparent behavioral, neurological or subjective effects. However, 5-HT2 antagonists increase slow wave sleep and have a therapeutic action on impaired circulation, dysthymia, and negative symptoms in schizophrenia. Chronic treatment of rodents with various 5-HT2 antagonists was reported to cause an anomalous desensitization and 5-HT2 receptor down regulation. In this study we further investigated the 5-HT2 receptor regulation in vivo and in vitro by agonist and antagonist treatment. Treatment of rats with the 5-HT2 agonist, 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) (2.5 mg/kg s.c., every 8 h), rapidly caused desensitization of the head twitch response (-20% and -80% after 2 and 4 injections) and a decrease in the number of frontal cortical 5-HT2 receptors labeled with [3H]ketanserin (-24% and -41%, 24 h after 2 and 4 injections). The receptor resynthesis/degradation revealed half-times of 5 days initially to 3 days in the later drug-free period. Administration of the antagonist ketanserin (2.5 mg/kg, s.c., every 8 h) 15 min before the agonist, antagonized the acute behavioral effect but did not prevent the 5-HT2 receptor down regulation after 4 treatments. In contrast, ketanserin by itself, given 4 times, caused a reduction in the Bmax-value of [3H]ketanserin binding by 19% and given 10 times it caused a reduction in the Bmax-values by 28% and 31% of [3H]ketanserin and [3H]DOB binding in the frontal cortex. Hence 5-HT2 receptors labeled by an antagonist and an agonist ligand were similarly decreased. In vascular smooth muscle cells in culture kept for at least 24 h in a serotonin-free medium before treatment, the 5-HT2 receptor mediated 5-HT-induced inositol phosphate formation, was rapidly desensitized by agonist treatment: -20% after 15 min and -80% after 1 h incubation of the cells with 10(-5) M 5-HT or DOM. After 2 h and 24 h treatment resensitization occurred with half-times of 5 h and 12 h, respectively. Pretreatment of the cells for 15 min or 24 h with 10(-7) M of the antagonists setoperone or ketanserin, followed by extensive washing, caused a reduction in the 5-HT-induced inositol phosphate formation by about 50% with setoperone and by 30% with ketanserin. Effects of 15 min and 24 h drug pretreatment were similar.(ABSTRACT TRUNCATED AT 400 WORDS)
Insights
Stimulation of serotonin 5-HT2 receptors by agonists causes negative effects, while antagonists offer therapeutic benefits. Both agonists and antagonists can lead to a decrease in 5-HT2 receptor density, impacting neurological and circulatory functions.
Area of Science:
- Neuroscience
- Pharmacology
- Cell Biology
Background:
- Serotonin 5-HT2 receptor agonists induce adverse neurological, psychological, and circulatory effects.
- 5-HT2 receptor antagonists mitigate these effects and show therapeutic potential for conditions like schizophrenia and impaired circulation.
- Chronic antagonist use in rodents has been linked to receptor desensitization and downregulation.
Purpose of the Study:
- To investigate the in vivo and in vitro regulation of 5-HT2 receptors following agonist and antagonist treatment.
- To examine the effects of DOM (agonist) and ketanserin (antagonist) on 5-HT2 receptor density and function.
- To understand the desensitization and resensitization mechanisms of 5-HT2 receptors.
Main Methods:
- Administered DOM (agonist) and ketanserin (antagonist) to rats, monitoring head twitch response and quantifying frontal cortical 5-HT2 receptors using [3H]ketanserin.
- Utilized cultured vascular smooth muscle cells to study 5-HT2 receptor-mediated inositol phosphate formation in response to 5-HT, DOM, setoperone, and ketanserin.
- Assessed receptor resensitization and degradation kinetics in vivo and in vitro.
Main Results:
- DOM treatment rapidly desensitized the head twitch response and decreased frontal cortical 5-HT2 receptor density.
- Ketanserin administration, even when given before the agonist, did not prevent agonist-induced receptor downregulation.
- Ketanserin alone, with repeated administration, reduced the binding of both antagonist ([3H]ketanserin) and agonist ([3H]DOB) ligands, indicating a decrease in total 5-HT2 receptors.
- In vitro, agonist treatment desensitized 5-HT2 receptor-mediated signaling, followed by resensitization.
- Antagonist pretreatment (ketanserin, setoperone) in vitro reduced receptor-mediated signaling without preventing subsequent desensitization.
Conclusions:
- Both 5-HT2 receptor agonists and antagonists can lead to a decrease in receptor number.
- The regulation of 5-HT2 receptors involves complex desensitization and resensitization processes.
- Findings suggest potential therapeutic implications for understanding 5-HT2 receptor modulation in various physiological and pathological conditions.